John Kelly, Founder, Managing Director & CEO and Will Souter, Chief Financial Officer, Atomo Diagnostics (ASX: AT1)
Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers.
Atomo has supply agreements in place for tests targeting infectious diseases including HIV, COVID-19, and viral vs bacterial differentiation.
Watch John Kelly and Will Souter's IRD Invest presentation in the window below.